Gastrointestinal Cancer

At the University of Virginia (UVA) Health System, the enhanced recovery after surgery (ERAS) program in colorectal cancer has improved outcomes of patients after procedures and reduced hospital costs.

According to new analysis, patients with metastatic colorectal cancer (mCRC) who engaged in daily exercise demonstrated improved outcomes.

A recent study links aspirin use to a reduced risk of pancreatic cancer.

A daily aspirin regimen could lower your risk of pancreatic cancer.

Patients with a recent diagnosis of diabetes mellitus (DM) and have undergone a surgical resection for pancreatic ductal adenocarcinoma may have poorer survival outcomes.

The incidence of hepatocellular carcinoma (HCC) in patients with hepatitis B is still on the rise, making screening and surveillance in this population all the more important.

Regorafenib was found to improve overall survival by nearly 3 months for patients with previously treated hepatocellular carcinoma.

With the mortality rate for liver cancer rising faster than the mortality rate for any other cancer, it is important that oncology nurses are aware of risk factors, screening, and treatments so they can pass information on to their patients.

Researchers analyzed Bing.com search logs to identify those recently diagnosed with pancreatic cancer. Through symptom patterns expressed as searches, they were able to identify 5% to 15% of pancreatic cancer cases.

Colorectal cancer mortality rates have been on the decline in California for both men and women since the mid-1990s, but for one group—Hispanic men—rates have remained essentially unchanged, and a new study suggests that lower rates of screening may be the chief driver of this disparity.

A large, population-based study found that obesity more prevalent in patients with a history of cancer than in the general population, suggesting an important area of focus and a need for improved weight management and control programs targeted at survivors’ specific needs.

Dave Dubin, founder of AliveAndKickn, discusses the importance of healthcare professionals knowing when to test for Lynch syndrome.

Mutations in BRCA1 and BRCA2, most commonly linked with breast and ovarian cancers, are now gaining wider recognition for being associated with pancreatic cancer as well.

For uninsured patients who are at a high risk for colorectal cancer (CRC), performing free screening colonoscopies can identify cancer at an earlier stage and appears to be cost neutral from a hospital system perspective.

Kyung Chu, RN, NYU Langone Perlmutter Cancer Center, discusses treating patients with different subtypes of KRAS mutation.

Barry Berger, MD, Exact Sciences Corporation, discusses Cologuard, an at-home screening for colorectal cancer.

Much work needs to be done to increase Lynch syndrome screening rates and better understand the factors that are associated with low testing rates.

A study published by researchers at the Dana Farber-Cancer Institute recently discovered that financial status plays a large role in the level of symptom burden and quality of life for patients newly diagnosed with lung or colorectal cancer.

Is there a treatment-related survival benefit for older patients with metastatic colorectal cancer?

Joseph Ravenell, MD, MS, from NYU Langone Medical Center, discusses access to screening among black men.

Racial disparities in mortality for breast cancer have gotten worse in women and persisted for colorectal cancer in men, although progress has been made in closing the mortality gap between blacks and whites for other cancers.

Joseph Ravenell, MD, MS, discusses some of the challenges with screening black men for colon cancer.

Danielle Novetsky Friedman, a general pediatrician in the Pediatric Long-Term Follow-Up Program at Memorial Sloan Kettering Cancer Center (MSK), discusses a study investigating the mechanisms leading to abnormal glucose and insulin dynamics in survivors of childhood cancers.

Robin B. Brenner, RN, CRN, OCN, clinical research nurse, David M. Rubinstein Center for Pancreatic Cancer Research, Memorial Sloan Kettering Cancer Center, discusses adverse events associated with Onivyde (irinotecan liposome injection; MM-398) for pancreatic cancer.

Results from clinical trials presented at the 2016 Gastrointestinal Cancers Symposium signal a role for the immunotherapy nivolumab (Opdivo) in the treatment of GI malignancies.

It is estimated that 1 million new cases are diagnosed in the world each year, and more than 723,000 deaths occur annually.

Michael Soulen, MD, a professor of radiology and surgery at the Abramson Cancer Center, University of Pennsylvania, discusses radioembolization to treat liver metastases in patients with neuroendocrine tumors (NETs) as well as the efficacy of embolization in treating NETs.